Results 241 to 250 of about 2,149,735 (308)

Integrative biomarker and drug target discovery in osteosarcoma: traditional experimental approaches and AI-enabled insights. [PDF]

Front Pharmacol
Gao Z, Wu C.
europepmc   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Erratum: A review of clinical pharmacology considerations in antibody-drug conjugates approved by the US Food and Drug Administration between 2000 and 2025. [PDF]

Transl Clin Pharmacol
Koo S, Kim CY, Lim JH, Lee E, Kim IY, Shin YG, Moon H.   +6 more
europepmc   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

When Selectivity Increases Uncertainty: Context-Dependent Pharmacology in Antibody Drug Development. [PDF]

Clin Transl Sci
Liao X, Cao Y.
europepmc   +1 more source

Precision oncology in the age of AI: lessons from AI-driven drug discovery and clinical translation. [PDF]

BJC Rep
Yoo W.
europepmc   +1 more source

New Trends in Sport Science-Observations From the 30th Annual Congress of the European College of Sport Science in Rimini. [PDF]

Eur J Sport Sci
Raastad T, Ferrauti A, Jones AM, Thompson JL.   +3 more
europepmc   +1 more source

Retraction Note: A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. [PDF]

Nat Commun
Li F, Lu J, Liu J, Liang C, Wang M, Wang L, Li D, Yao H, Zhang Q, Wen J, Zhang ZK, Li J, Lv Q, He X, Guo B, Guan D, Yu Y, Dang L, Wu X, Li Y, Chen G, Jiang F, Sun S, Zhang BT, Lu A, Zhang G.   +25 more
europepmc   +1 more source

Comment on: Fibrinogen Changes Before and After Intravenous Thrombolysis as Predictors of Cerebral Injury and Clinical Outcomes in Acute Ischemic Stroke—The 24‐h Time‐Point May be a Pro‐Thrombotic Blind Spot: Check 6‐h Fibrinogen Rebound to Catch Early Re‐Occluders

Annals of Clinical and Translational Neurology, EarlyView.
Qichao Fang, Luting Ying, Yongjin Gong
wiley   +1 more source